A brain AVM (arteriovenous malformation) is a tangle of abnormal blood vessels where arteries connect directly to veins, bypassing the tiny capillaries that normally slow blood flow and deliver oxygen to brain tissue. This creates a high-pressure, high-flow shortcut that can weaken surrounding vessels over time, raising the risk of bleeding into the brain. Brain AVMs affect roughly 18 per 100,000 adults and are present from birth in most cases.
How a Brain AVM Works
In a healthy brain, blood travels from arteries into progressively smaller vessels called capillaries. Capillaries have thin walls that allow oxygen and nutrients to pass into brain cells. Blood then collects into veins at low pressure and returns to the heart. An AVM skips this entire middle step. Arterial blood, still at high pressure, rushes directly into veins that aren’t built to handle it.
Over years, this constant high-pressure flow can stretch and weaken the veins and the tangled knot of vessels (called the nidus) at the center of the malformation. The result is a fragile structure sitting inside the brain, quietly carrying a risk of rupture. Some AVMs are tiny, smaller than a centimeter. Others can span several centimeters and involve deep regions of the brain.
What Causes Them
Most brain AVMs form during fetal development, though the exact reason isn’t well understood. They are not typically inherited, but a small number of cases are linked to a genetic condition called hereditary hemorrhagic telangiectasia (HHT), which affects blood vessel formation throughout the body, including the brain. In rare instances, AVMs can also develop later in life.
Symptoms and How AVMs Are Found
About 15% of people with brain AVMs have no symptoms at all, and their AVM is discovered incidentally during imaging for an unrelated problem. For the rest, symptoms depend largely on where the AVM sits in the brain and whether it has bled.
The most common first sign is a brain hemorrhage, which accounts for roughly two-thirds of initial presentations. This can cause a sudden, severe headache, nausea, vision changes, weakness on one side of the body, confusion, or loss of consciousness. About one in five people with a brain AVM first presents with seizures. Chronic headaches without other neurological signs are actually a rare way for AVMs to come to attention, occurring in only about 0.3% of people who seek care for headaches.
Some people experience focal neurological problems like numbness, difficulty speaking, or coordination issues. These were historically attributed to a “steal phenomenon,” the idea that the AVM diverts blood away from healthy brain tissue. However, research has found insufficient evidence that steal actually explains symptoms in most patients.
How Brain AVMs Are Diagnosed
AVMs are often first spotted on a CT scan or MRI performed after a hemorrhage or seizure. CT angiography provides good vascular detail of the malformation, while MRI and magnetic resonance angiography are better at showing the AVM’s relationship to surrounding brain structures.
The gold standard for a definitive diagnosis is cerebral angiography, a procedure where contrast dye is injected into the blood vessels and X-ray images are taken in real time. This reveals the feeding arteries, the nidus, the draining veins, and any associated aneurysms or structural weaknesses. One key finding is an early-draining vein visible during the arterial phase of imaging, which confirms that blood is shunting directly from arteries to veins.
Risk of Bleeding
The annual risk of hemorrhage from a brain AVM is roughly 2% to 4% per year overall. For AVMs that have never bled, that number sits closer to 2% per year. If the AVM has already ruptured once, the annual risk rises to about 4.5%. These numbers may sound small in any single year, but they compound over a lifetime. A 30-year-old with an unruptured AVM faces a cumulative risk that grows significantly over the following decades.
Several factors influence individual risk: the size of the AVM, the pattern of its venous drainage, the presence of associated aneurysms, and its location in the brain. Doctors use a grading system developed by Spetzler and Martin that scores AVMs based on three variables: size, whether the AVM drains into deep or superficial veins, and whether it sits in a region of the brain that controls critical functions like speech or movement (called “eloquent” brain). A lower score generally means lower surgical risk.
Treatment Options
Treatment decisions for brain AVMs are highly individualized. The three main approaches can be used alone or in combination.
- Microsurgery: A neurosurgeon opens the skull and physically removes the AVM. This is the most direct option and offers the highest chance of complete elimination in a single procedure. It works best for smaller, superficially located AVMs with low Spetzler-Martin grades.
- Stereotactic radiosurgery: Focused beams of radiation are aimed precisely at the nidus. The radiation causes the abnormal vessels to thicken and close over time, typically over two to three years. This approach is useful for smaller AVMs or those in deep, hard-to-reach locations.
- Endovascular embolization: A catheter is threaded through the blood vessels to the AVM, and a glue-like material is injected to block blood flow within the nidus. Embolization is often used before surgery to reduce the size and blood flow of the AVM, making the operation safer. It can also be used to protect critical brain areas during treatment.
Embolization alone achieves complete closure of the AVM in roughly 5% to 40% of cases, depending on size and anatomy. Very small AVMs (under 1 cm) have much higher success rates with embolization, up to 85% in some series. For larger AVMs, a combination of embolization followed by surgery or radiosurgery is common. When embolization is paired with radiosurgery, cure rates of 76% to 78% have been reported for AVMs smaller than 4 cm, dropping to 59% for those between 4 and 6 cm, and just 7% for the largest malformations.
For some patients, particularly those with large, high-grade AVMs that have never bled, doctors may recommend careful monitoring rather than immediate treatment. The decision weighs the natural risk of hemorrhage against the risks of the procedure itself.
Age and Demographics
Brain AVMs can be diagnosed at any age, though most come to medical attention between the teens and the 40s. In population studies, men tend to be diagnosed younger than women, with a median age of 39 compared to 51. This likely reflects differences in when symptoms appear rather than differences in who develops them. Because AVMs are present from birth in most cases, they may sit silently in the brain for decades before causing any trouble.